0))

To the European Patent Office

Entry into the European phase (EPO as designated or elected Office)

European application number		
PCT application number	PCT/IB2003/05272	
PCT publication number		
Applicant's or representative's reference	PHNL021275EP	
 Applicant Particulars of the applicant(s) are contained in the international publication or were recorded by the International Bureau subsequent to the international publication. 	Ø	
Changes which have not yet been recorded by the International Bureau are set out here:		
Address for correspondence		
2. Representative 1		
This is the representative who will be listed in the Register of European Patents and to whom notifications will be made Name Address of place of business	GROENENDAAL, Antonius, W., M. Philips Intellectual Property & Standards	
	P.O. Box 220 NL-5600 AE Eindhoven Netherlands	
Telephone	+31 40 2743505	
Fax	+31 40 2743489	
e-mail		
Any additional representative(s) is/are listed here:		
3. Authorisation		
An individual authorisation is attached.		
A general authorisation has been registered under No:		
A general authorisation has been filed, but not yet registered.		
The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase.		
4. Request for examination Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid.	Ø	
Request for examination in an admissible non-EPO language:	☑ Verzocht wordt om onderzoek van de aanvrage als bedoeld in Art. 94.	

One or more additional sets of copies of the documents cited in the supplementary	
European search report are hereby requested.	
Number of additional sets of copies	
6. Documents intended for proceedings before the EPO	
6.1 Proceedings before the EPO as designated Office (PCT I) are to be based on the following documents:	
the application documents published by the International Bureau (with all claims, description and drawings), where applicable with amended claims under Art. 19 PCT	
unless replaced by the amendments attached.	
Where necessary, clarifications should be attached as 'Other Documents'	
6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following documents:	
the documents on which the international preliminary examination report is based, including any annexes	\square
unless replaced by the amendments attached.	
Where necessary, clarifications should be attached as 'Other Documents'	
,, , , , , , , , , , , , , , , , , , ,	
If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.	\square
reports, these may be used as the basis of proceedings before the EPO.	☑
	☑
reports, these may be used as the basis of proceedings before the EPO. 7. Translations Translations in one of the official languages of the EPO (English, French, German) are	☑
7. Translations Translations Translations of the official languages of the EPO (English, French, German) are attached as crossed below:	
7. Translations Translations Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below: * In proceedings before the EPO as designated or elected Office (PCT I + II): Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under	
7. Translations Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below: * In proceedings before the EPO as designated or elected Office (PCT I + II): Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material	
7. Translations Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below: In proceedings before the EPO as designated or elected Office (PCT I + II): Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material Translation of priority application(s) It is hereby declared that the international application as originally filed is a complete	
7. Translations Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below: * In proceedings before the EPO as designated or elected Office (PCT I + II): Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material Translation of priority application(s) It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 38(5) EPC)	
7. Translations Translations Translations one of the official languages of the EPO (English, French, German) are attached as crossed below: * In proceedings before the EPO as designated or elected Office (PCT I + II): Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material Translation of priority application(s) It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 38(5) EPC) * In addition, in proceedings before the EPO as designated Office (PCT I): Translation of amended claims and any statement under Art. 19 PCT, if the claims as	
7. Translations Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below: * In proceedings before the EPO as designated or elected Office (PCT I + II): Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material Translation of priority application(s) It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 38(5) EPC) * In addition, in proceedings before the EPO as designated Office (PCT I): Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6).	

8. Biological material The invention relates to and/or uses biological material deposited under Rule 28 EPC.	
The particulars referred to in Rule 28(1)(c) EPC (if not yet known, the depository institution and the identification reference(s) [number, symbols, etc.] of the depositor) are given in the international publication or in the translation submitted under Section 7 on:	
page(s) / line(s)	
A copy of the receipt(s) of deposit issued by the depositary institution	
is attached	
will be filed at a later date	
A walver of the right to an undertaking from the requester pursuant to Rule 28(3) EPC is attached.	
9. Nucleotide and amino acid sequences	
The items required under Rules 5.2 and 13ter PCT and Rule 111(3) EPC have already been furnished to the EPO.	
The sequence listing as part of the description is attached in PDF format.	
The sequence listing does not include matter that goes beyond the content of the application as filed.	
In addition, the sequence listing data is attached in computer-readable form in accordance with WIPO Standard 25.	
The sequence listing data in computer-readable form in accordance with WIPO Standard 25 is identical to the sequence listing in PDF format.	0
10. Designation fees	
10.1 It is currently intended to pay seven times the amount of the designation fee. The designation fees for all the EPC contracting states designated in the international application are thereby deemed to have been paid (Art. 2 No. 3 RFees).	\square
AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR	
10.2 The declaration in No. 10.1 does not apply. Instead, it is currently intended to pay fewer than seven designation fees for the following EPC contracting states designated in the International application:	
It is requested that no communications under Rule 108(3) EPC be issued in respect of any contracting states not indicated.	
10.3 If an automatic debit order has been issued (Section 12), the EPO is authorised, on expiry of the basic period under Rule 107(1)(d) EPC, to debit seven times the amount of the designation fee. If states are indicated in No. 10.2, the EPO will debit designation fees for those states only, unless instructed otherwise before the basic period expires.	

•

non-contracting states to "extension agreements" w	This application is also considered as being a request for extension to all the ion-contracting states to the EPC designated in the international application with which extension agreements" were in force on the date of filing the international application. towever, the extension only takes effect if the prescribed extension fee is paid.			Ø	
	pay the extension fee for the				
12. Automatic debit or			<u> </u>		
Currency			EUR		
procedure, to debit from the designation fees, see "State for paying the extension for paying th	he deposit account below ates".The EPO is also auti ees, to debit those fees for	nents for the automatic debit any fees and costs falling di norised, on expiry of the bas reach of the "extension stat fore the said period expires	ue. For ic period es"		
Denocit account number			28090021		
	osit account number		Philips Intern	Philips International B.V IP&S	
Account holder 13. Reimbursements (ideposit account: Number and account hold		de to the following EP	o <u>A</u>	nilips International B.V IF	
Account holder 13. Reimbursements (ideposit account:			O ☑ 28090021, P		
Account holder 13. Reimbursements (ideposit account: Number and account hold		de to the following EP	o <u>A</u>	Amount to be paid	
Account holder 13. Reimbursements (ideposit account: Number and account hold	Total:	Factor applied	28090021, P	Amount to be paid	
Account holder 13. Reimbursements (i deposit account: Number and account hold 14. Fees 15. Annotations	Total:	Factor applied	28090021, P	Amount to be paid	
Account holder 13. Reimbursements (indeposit account: Number and account hold 14. Fees 15. Annotations 16. Signature(s) of appropriate: Date:	Total:	Factor applied	28090021, P	Amount to be paid	
Account holder 13. Reimbursements (indeposit account: Number and account hold 14. Fees 15. Annotations 16. Signature(s) of appropriate in the property	Total: Dicant(s) or represer Elndhoven 21 April 2005 Subject: NL, Phili	Factor applied	28090021, P Fee schedule EUR	Amount to be paid 0	
Account holder 13. Reimbursements (indeposit account: Number and account hold 14. Fees 15. Annotations 16. Signature(s) of appropriate: Date:	Total: Dicant(s) or represer Elndhoven 21 April 2005 Subject: NL, Phili	Factor applied Itative ps IP&S, J. van der Ve un Patent Office, Euro	28090021, P Fee schedule EUR	Amount to be paid 0	